Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 9, 2005

View Archived Issues

AstraZeneca: Q3 update

Introgen and Colgate-Palmolive form oral care alliance

Fovea completes Series A financing to develop drugs for retinal diseases

Emisphere receives FDA guidance on oral heparin phase III trial

OT-551 begins phase II trial in cataract prevention

Kos and Jerini sign agreement for icatibant in U.S. and Canada

Safety milestone in Osiris' stem cell trial for heart attack patients

Bionomics reviews operations

Mechanistic profile of Intermune's agents for IPF

Probenecid may halve the needed dose of oseltamivir

New tool to assess role of alpha1D- and alpha1B-ARs in prostate cancer

Hepcidin - a new target to prevent anemia of inflammation

Novel compounds with potential use in cardiovascular diseases reported

Not approvable letter for premature ejaculation drug dapoxetine

Recent patents disclose novel agents for dermatological disorders

Novel oligonucleotides for immunological disorders emerge from Coley R&D

Complement inhibition may reduce injury in coronary bypass surgery patients

Brivaracetam granted orphan drug status for symptomatic myoclonus

Meta-analyses reveal efficacy of gemifloxacin in resistant infections and high-risk patients

New data confirms the benefits of sitaxsentan in PAH

Update on the pharmacokinetics of alvimopan

A second phase III study confirms the therapeutic benefits of ranibizumab in AMD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 5, 2025.
MicroRNAs in circulating extracellular vesicles as IPF biomarkers
BioWorld Science
MicroRNAs (miRNAs) are small noncoding RNAs gaining increasing attention due to their crucial role in gene expression regulation and influence in various cellular...
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...